Cornel Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.60 M
- Company Age 40 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -58.22%
- Profit Growth -42.76%
- Ebitda -36.56%
- Net Worth 27.25%
- Total Assets -26.39%
About Cornel Pharmaceuticals
Cornel Pharmaceuticals Private Limited (CPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 12 June 1984 and has a history of 40 years and seven months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.60 M, as per Ministry of Corporate Affairs (MCA) records.
Keerthi, Sharmila Parekh, and Vaibhav Parekh serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51100GJ1984PTC006998
-
Company No.
006998
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Jun 1984
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Cornel Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Keerthi
|
Director | 30-Jun-2011 | Current |
|
Sharmila Parekh
|
Director | 01-Jul-2019 | Current |
|
Vaibhav Parekh
|
Director | 23-May-2018 | Current |
Financial Performance of Cornel Pharmaceuticals.
Cornel Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 58.22% decrease. The company also saw a substantial fall in profitability, with a 42.76% decrease in profit. The company's net worth Soared by an impressive increase of 27.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cornel Pharmaceuticals?
In 2023, Cornel Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Almet Lifesciences Private LimitedVaibhav Parekh is a mutual person
-
Everstar Enterprises LlpVaibhav Parekh is a mutual person
-
Vinny Health Care Private Limited
Vaibhav Parekh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cornel Pharmaceuticals?
Cornel Pharmaceuticals has a workforce of 1 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cornel Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cornel Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
